Suspected and Non-Targeted Screening of Non-Edible Substances in Food by UPLC-Q-TOF-MS
Abstract
A screening method based on dispersive solid-phase extraction (DSPE) coupled with ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was established for the analysis of non-edible substances in food. This method is applicable to a wide range of non-edible substances, including but not limited to antihypertensive, hypoglycemic, weight-loss, antimicrobial, antipyretic-analgesic, sedative-hypnotic, and antifatigue agents. Through systematic optimization of sample pretreatment and UPLC-Q-TOF-MS conditions, ultrasonic extraction with methanol followed by cleanup using 25 mg Primary Secondary Amine (PSA) and 50 mg C18 was identified as the optimal procedure. The methodological validation demonstrated that all 38 quality control compounds exhibited excellent linear correlation coefficients (R2 > 0.99) across a concentration range of 0.005~5.0 mg/kg. At three spiking levels, the mean recoveries and relative standard deviations (RSDs) in four matrices ranged from 67.79% to 110.93% and from 0.23% to 9.37%, respectively. The screening detection limits (SDLs) and limits of quantification (LOQs) were within the range of 0.003~0.5 mg/kg. A screening database comprising 390 substances was constructed. In addition, an identification strategy for the unknown structural analogues was established by summarizing the mass spectrometric fragmentation patterns of the phosphodiesterase-5 (PDE-5) inhibitor analogues. Applied to 110 batches of samples,…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.